中医临床研究
中醫臨床研究
중의림상연구
CLINICAL JOURNAL OF CHINESE MEDICINE
2013年
10期
38-39
,共2页
肺癌%中医药疗法%肺积方
肺癌%中醫藥療法%肺積方
폐암%중의약요법%폐적방
Lung cancer%TCM treatment%The Feiji recipe
目的:研究中药肺积方治疗晚期非小细胞肺癌患者的临床疗效和作用机理。方法:患者104例随机分为三组:中药组予中药肺积方治疗;西药组常规化学治疗;中西组肺积方与化疗结合治疗。结果:近期疗效:KPS评分三组治疗后均高于治疗前,提高幅度中药组优于中西组,中西组又优于西药组(P<0.01)。远期疗效:三组患者平均生存时间、中位生存期、0.5年生存率、1年生存率均显示中西组高于中药组和西药组(P<0.05),中药组和西药组生存期相当(P>0.05)。TNF-α三组治疗后均低于治疗前,下降幅度中药组优于中西组,中西组又优于西药组(P<0.05)。结论:中药肺积方对晚期NSCLC具有一定的客观疗效,主要表现为稳定病灶、提高生活质量、延长生存期。
目的:研究中藥肺積方治療晚期非小細胞肺癌患者的臨床療效和作用機理。方法:患者104例隨機分為三組:中藥組予中藥肺積方治療;西藥組常規化學治療;中西組肺積方與化療結閤治療。結果:近期療效:KPS評分三組治療後均高于治療前,提高幅度中藥組優于中西組,中西組又優于西藥組(P<0.01)。遠期療效:三組患者平均生存時間、中位生存期、0.5年生存率、1年生存率均顯示中西組高于中藥組和西藥組(P<0.05),中藥組和西藥組生存期相噹(P>0.05)。TNF-α三組治療後均低于治療前,下降幅度中藥組優于中西組,中西組又優于西藥組(P<0.05)。結論:中藥肺積方對晚期NSCLC具有一定的客觀療效,主要錶現為穩定病竈、提高生活質量、延長生存期。
목적:연구중약폐적방치료만기비소세포폐암환자적림상료효화작용궤리。방법:환자104례수궤분위삼조:중약조여중약폐적방치료;서약조상규화학치료;중서조폐적방여화료결합치료。결과:근기료효:KPS평분삼조치료후균고우치료전,제고폭도중약조우우중서조,중서조우우우서약조(P<0.01)。원기료효:삼조환자평균생존시간、중위생존기、0.5년생존솔、1년생존솔균현시중서조고우중약조화서약조(P<0.05),중약조화서약조생존기상당(P>0.05)。TNF-α삼조치료후균저우치료전,하강폭도중약조우우중서조,중서조우우우서약조(P<0.05)。결론:중약폐적방대만기NSCLC구유일정적객관료효,주요표현위은정병조、제고생활질량、연장생존기。
Objective:To observe the effect of Feiji recipe in the treatment of advanced NSCLC. Methods:104 advanced NSCLC patients were randomly divided into three groups:TCM group (27 cases), modern medicine(MM) group (37 cases), combined TCM with MM group (40 cases). Results:Short-term effect:The KPS scores after treatment in all three groups were higher than the pre-treatment. The rise in TCM group was superior to combined TCM with MM group, combined TCM with MM group was superior to WM group (P<0.01). Long-term effect: The average survival time, median survival time, half year survival rate, 1year survival rate, and survival curves had shown that combined TCM with MM group was higher than that of TCM and MM group (P<0.05). TNF-αin three groups after treatment were lower than in the pre-treatment. The decrease in TCM group was superior to combined TCM with MM group, then combined TCM with MM group was superior to MM group (P<0.05). Conclusion: The Feiji recipe has certain objective efficacy on treating advanced NSCLC, mainly shows in stabilizing lesions, improving the QOL and prolonging survival.